QUOTE AND NEWS
FiercePharma  Mar 24  Comment 
The FDA says it won't recommend new limits on Eli Lilly schizophrenia med Zyprexa Relprevv after almost a year of investigating the deaths of two patients 3 to 4 days after they received injections.
Benzinga  Mar 23  Comment 
In a report published Monday, Cowen and Co analysts maintained an Outperform rating on Eli Lilly and Company (NYSE: LLY), while raising the price target from $78 to $85, after the release of BIIB037 data. In the report Cowen noted, "Several...
TheStreet.com  Mar 23  Comment 
NEW YORK (Real Money) -- Lilly  is moving further into new 52-week-high territory. The stock began this impressive move with a short-term trendline break a week ago. LLY got a big bump two days later with a news-inspired (Hanmi joint venture)...
TheStreet.com  Mar 23  Comment 
NEW YORK (TheStreet) -- Eli Lilly shares are up 1.32% to $77.12 in afternoon trading on Monday after the company announced that it would continue late-stage studies with Pfizer  for their chronic pain drug, tanezumab, after the Food and...
Jutia Group  Mar 23  Comment 
[Reuters] - The U.S. Food and Drug Administration said it would not recommend changes to the prescribing or use of Eli Lilly and Co's schizophrenia drug after a review of two deaths. Elevated levels of the drug, Zyprexa ... Read more on this. Eli...
Benzinga  Mar 20  Comment 
Eli Lilly and Co (NYSE: LLY) unveiled one of the largest biotech collaborations in China to date in a deal aimed at cancer drugs. Lilly changed hands recently at $74.67, up $0.45. Indianapolis-based Lilly will team up with China-based...
GenEng News  Mar 20  Comment 
Eli Lilly will join Innovent Biologics to co-develop and co-commercialize at least three cancer treatments over the next decade, in a deal that could generate up to $456 million for the Chinese biopharma. Under their agreement, Innovent will...
TheStreet.com  Mar 19  Comment 
NEW YORK (TheStreet) -- Eli Lilly shares are up 1.28% to $74.48 in trading on Thursday after the pharmaceutical and animal health company agreed to an exclusive license and collaboration agreement with Hanmi Pharmaceuticals to develop...
GenEng News  Mar 19  Comment 
Eli Lilly will join in developing and commercializing Hanmi Pharmaceutical's Phase I compound HM71224 for autoimmune and other diseases, in a deal that could generate up to $690 million, plus royalties, for Hanmi. HM71224 is an oral Bruton's...




 

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki